SCHEDULE: Armistice Capital Discloses Kura Oncology Stake

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 3,736,000 shares, representing 4.23% of Kura Oncology, Inc.'s common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, indicating their beneficial ownership of Kura Oncology, Inc. common stock.
• The filing reports a total of 3,736,000 shares owned, which constitutes 4.23% of the class of securities.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own these shares.
• The Master Fund disclaims beneficial ownership due to the investment management agreement with Armistice Capital.
• The filing is an amendment to a previous filing, with the event date requiring this statement being March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of a significant ownership stake, providing transparency without inherently signaling positive or negative performance for Kura Oncology.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed their significant stake in Kura Oncology, Inc., providing transparency to the market.
• The reporting persons hold a substantial 4.23% of the company's common stock, indicating confidence or strategic interest.

Negatives

• The Master Fund, the direct holder of the shares, explicitly disclaims beneficial ownership, which could imply a lack of direct control or strategic intent from the fund itself.

Risks

• The filing does not explicitly mention any risks or challenges faced by the company or the reporting persons.

Future Outlook

No specific forward-looking statements or guidance are provided in this Schedule 13G filing.

Management Comments

• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to disclose their holdings. This filing indicates Armistice Capital's substantial investment in Kura Oncology, a biotechnology company focused on oncology, a highly competitive and research-intensive sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership, potentially influencing market perception and trading activity.
• Management: Awareness of a substantial shareholder with potential influence on corporate strategy or governance.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Continued monitoring of Armistice Capital's activities and potential future filings related to Kura Oncology.

Key Dates

Keywords

Kura Oncology, Schedule 13G, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Common Stock, Investment Management